Clinical trials: Atopic Skin
Atopic Dermatitis
Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)
This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.
- Trial name
- ADjoin (NCT04392154)
- Testing
- Lebrikizumab
- Where
- 321 sites in United States, Australia and 14 more
- Volunteers
- 1,153 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis
To investigate the safety and tolerability of repeated subcutaneous (s.c.) doses of MOR106 administered concomitantly with topical corticosteroids (TCS) in participants with moderate to severe atopic dermatitis (AD) who are…
- Trial name
- GECKO (NCT03864627)
- Testing
- MOR106
- Where
- 14 sites in United States
- Volunteers
- 33 people
- Sponsor
- Lakefront Biotherapeutics NV
Atopic Dermatitis
Study of OPA-15406 Ointment in Patients With Atopic Dermatitis
The purpose of this study is to assess the efficacy and safety of OPA-15406 ointment in patients with atopic dermatitis.
- Trial name
- NCT02914548
- Testing
- OPA-15406
- Where
- 3 sites in Japan
- Volunteers
- 200 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Dermatitis, Atopic
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
The main objective of the trial is to demonstrate the efficacy of dupilumab administered concomitantly with topical corticosteroids (TCS) in participants ≥6 years to <12 years of age with severe atopic dermatitis (AD).
- Trial name
- NCT03345914
- Testing
- Dupilumab, Background Treatment: Topical Corticosteroids, Background Treatment: Moisturizers
- Where
- 61 sites in United States, Canada and 4 more
- Volunteers
- 367 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis
The purpose of this study is to evaluate the long-term safety and efficacy of baricitinib in participants with atopic dermatitis.
- Trial name
- BREEZE-AD3 (NCT03334435)
- Testing
- Baricitinib
- Where
- 185 sites in Argentina, Australia and 17 more
- Volunteers
- 1,645 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis
The purpose of this study is to determine whether etrasimod is a safe and effective treatment for moderate-to-severe atopic dermatitis (AD).
- Trial name
- ADVISE (NCT04162769)
- Testing
- Etrasimod 1 mg, Etrasimod 2 mg
- Where
- 38 sites in United States, Australia and 1 more
- Volunteers
- 140 people
- Sponsor
- Arena Pharmaceuticals
Atopic Dermatitis
An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis
The purpose of this study is to evaluate the safety and effectiveness of four dose regimens (pattern of giving treatment) of JNJ-26113100 in the treatment of adult Atopic Dermatitis ([AD]; skin rash, inflammation) that is…
- Trial name
- NCT00455429
- Testing
- JNJ-26113100 (50 mg) once daily, JNJ-26113100 (100 mg) once daily, JNJ-26113100 (100 mg) twice daily
- Where
- 19 sites in United States
- Volunteers
- 84 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Eczema
Test to Determine the Effectiveness of Moisturizing Balm Used on Babies With Dry, Itchy Skin
The purpose of this 3 week study is to test the effectiveness of an over-the-counter (OTC) skin balm in infants and toddlers with mild to moderate dry, itchy skin.
- Trial name
- NCT02404493
- Testing
- EpiCeram Skin Barrier Emulsion, 1% Colloidal Oatmeal Balm
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Atopic Dermatitis
A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)
The primary objective of the study was to assess the ability of different Dupilumab dose regimens, administered as monotherapy, to maintain the treatment response achieved after 16 weeks of initial treatment with Dupilumab…
- Trial name
- SOLO-CONTINUE (NCT02395133)
- Testing
- Dupilumab
- Volunteers
- 422 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
The purpose of this study is to evaluate the safety and effectiveness of Baricitinib in eczema.
- Trial name
- NCT02576938
- Testing
- Baricitinib, Triamcinolone (Optional)
- Where
- 13 sites in United States, Japan
- Volunteers
- 124 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis
The purpose of this study is to establish the efficacy of each strength of ruxolitinib cream once daily (QD) or twice daily (BID) in participants with atopic dermatitis as compared with vehicle cream BID.
- Trial name
- NCT03011892
- Testing
- Ruxolitinib 0.15% Cream QD, Ruxolitinib 0.5% Cream QD, Ruxolitinib 1.5% Cream QD
- Where
- 52 sites in United States, Canada
- Volunteers
- 307 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis
The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis
Staphylococcus aureus (S. aureus) infection is perceived not only as a common secondary complication of atopic dermatitis (AD), but also as a culprit in the worsening of this condition.
- Trial name
- NCT00179959
- Testing
- Sodium hypochlorite (bleach) baths, Mupirocin ointment, Water
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Northwestern University
Atopic Dermatitis
The Effectiveness of Montelukast on Atopic Dermatitis in Koreans
The purpose of this study is to assess the clinical effectiveness of Montelukast in children (2~6 years old) with atopic dermatitis and identify the pathophysiologic background of Montelukast on the role of modulating the atopic…
- Trial name
- NCT00903357
- Where
- South Korea
- Volunteers
- 54 people
- Sponsor
- Pyun BokYang
Atopic Dermatitis
A Study to Investigate the Use of Hydrogel Vehicle in Maintaining the Skin Barrier in Persons With Atopic Dermatitis
While the repair of the epidermal barrier in atopic dermatitis is of major importance in the treatment of atopic dermatitis, most of the vehicles used may actually cause a worsening of an impaired epidermal barrier.
- Trial name
- NCT01065714
- Testing
- Hydrogel vehicle, Eucerin Lotion
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Derm Research, PLLC
Atopic Dermatitis
Study to Evaluate Safety and Tolerability of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis
This is the first time PF-07242813 will be given to humans. The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07242813 in healthy participants and…
- Trial name
- NCT04668066
- Testing
- PF-07242813
- Where
- 7 sites in United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Pfizer
Atopic Dermatitis
Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis
This is a first-in-human, randomized, double-blind, parallel-group, vehicle-controlled study to evaluate the efficacy, safety, tolerability, and PK of ATI-1777 solution following twice-daily applications to target areas of…
- Trial name
- NCT04598269
- Testing
- ATI-1777, Vehicle
- Where
- 14 sites in United States
- Volunteers
- 50 people
- Sponsor
- Aclaris Therapeutics, Inc.
Atopic Dermatitis
Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2, multicenter, randomized, placebo-controlled, double-blind, parallel-group study for subjects with moderate to severe AD whose disease cannot be adequately controlled with topical medications or for whom topical…
- Trial name
- NCT03703102
- Testing
- KHK4083
- Where
- 58 sites in United States, Canada and 2 more
- Volunteers
- 274 people
- Sponsor
- Kyowa Kirin, Inc.
Atopic Dermatitis
LEO 29102 Cream in the Treatment of Atopic Dermatitis
This is a proof of concept and dose finding Phase II trial comparing 5 dose strengths with vehicle and an active comparator (Elidel cream 10 mg/g) in a 4 week, twice daily treatment regimen in mild to moderate atopic dermatitis…
- Trial name
- NCT01037881
- Testing
- LEO 29102, Elidel®
- Where
- 3 sites in Canada, Finland and 1 more
- Volunteers
- 183 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis
The purpose of the study is to compare the efficacy and safety of benralizumab versus placebo and to compare benralizumab dosing regimens during extension period.
- Trial name
- NCT04605094
- Testing
- Benralizumab
- Where
- 51 sites in United States, Australia and 6 more
- Volunteers
- 194 people
- Sponsor
- AstraZeneca
Dermatitis, Atopic
Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis
The purpose of this study is to investigate the safety and efficacy of AN2728 Topical Ointment, 2% in children, adolescents, and adults (ages 2 years and older) with atopic dermatitis.
- Trial name
- NCT02118766
- Testing
- AN2728 Topical Ointment, 2%, Matching vehicle control
- Where
- United States
- Volunteers
- 763 people
- Sponsor
- Pfizer